Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial☆

Annals of Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles